HPTN 2023 State of the Network

Myron S. Cohen, MD Wafaa M. El-Sadr, MD, MPH, MPA HPTN Principal Investigators



Network Structure – Leaders





Myron S. Cohen



Wafaa El-Sadr

Executive Committee (EC)

- Myron S. Cohen
- Wafaa El-Sadr
- Quarraisha Abdool Karim
- Chris Beyrer
- Sinead Delany-Moretlwe
- Deborah Donnell
- Susan Eshleman
- Sybil Hosek
- Raphael Landovitz
- Nyaradzo Mgodi
- David Serwadda
- Sten Vermund
- Nirupama Sista
- Melissa Turner
- Darrell Wheeler
- 2 NIH Representatives

Leadership and Operations Center (LOC) FHI 360



Statistical and Data Management Center (SDMC) SCHARP



Deborah Donnell

Laboratory Center (LC) Johns Hopkins University



Susan Eshleman



Mark Marzinke



78 Trials ongoing or completed



172,000+ Study participants enrolled



History: HPTN Research Evolution



Cates & Self

Vaccines Microbicides MTCT ART Prevention STI Treatment Substance Use Behavioral Structural Intervention

1993

IMC/HIVNET

Cates & Coates

Vaccines Microbicides MTCTII ART STI Treatment Substance Use Behavioral Structural Intervention

1999

HPTNI

Vermund & Abdool-Karim

Vaccines Microbicides MTCT TaSP (052) IIII STI Treatment Substance Use Behavioral Structural Intervention

2006

HPTN II

El-Sadr & Cohen

Integrated Strategies: Biomedical Behavioral Structural Oral PrEPIII Alternate drugs, regimens, and formulations Phase I to III

2013

HPTN III

El-Sadr & Cohen

LA-PrEP!!

Multipurpose technology Broadly-neutralizing antibodies as PrEP Integrated strategies -Trans prevention! -PWID!

Heterosexeual men Pregnant women STI Vaccines ?


2020 HPTN IV

UNDETECTABLE 🗖 UNTRANSMITTABLE



The impact of Fast-Track


New HIV infections in low- and middle-income countries



Business as usual (no scale-up)

Fast-Track results (rapid scale-up)


AIDS-related deaths in low- and middle-income countries



UNN AIDS 05-895-95 01506_JC2743_Understanding_FastTrack_en

Forward: 2023 Clinical Research Sites





69 HPTN Sites

13 Countries

22 African Sites

5 Asian Sites

31 North American Sites

11 South American Sites

Two Points to Consider First



- HPTN/HVTN = The COVID Prevention Network (CovPN)
- Moderna, Astra Zeneca, J&J, Novavax vaccines
- mAbs from Lilly, Regeneron and Astra Zeneca


But.. Consider the HPTN/HVTN Opportunity Costs

Recent HVTN Vaccine Trials

-HIV vaccine development continues to prove VERY challenging -Collaborative HVTN/HPTN bnAb research for next PrEP -bnAb research informs vaccine development, long-term

Achieving Population Impact





NEXT in PrEP





CAB LA PrEP IS APPROVED in the U.S. – What's Next?



- Open label extension (OLE) studies will estimate continued safety and protection, PK, resistance, and include pregnancy and adolescent substudies.
- CAB LA for PrEP is approved in several countries, including Botswana, Malawi, South Africa, Zambia and Zimbabwe. In addition, full EMA approval was received for use in EU countries.
- ROUND OF APPLAUSE!!!!!
- New studies in development to examine the effectiveness of CAB-LA among adolescents and PWID.
- New studies to explore different routes of administration (e.g., thigh). fewer injections/year and more.
- Combine cabotegravir-LA with contraceptives in future studies?

Pregnancy Sub-Study in HPTN 084 OLE



- Estimate the incidence of pregnancy among participants during the OLE period
- Evaluate safety and infant outcomes among pregnant participants
- Evaluate the PK of CAB LA among pregnant participants, combining blinded, unblinded and OLE periods
- Evaluate concentration in breastmilk and infants among women who receive CAB LA injections during pregnancy and/or the early post-partum period.


The HPTN/Gilead Collaboration: A New paradigm



- Lenacapavir, a first-in-class selective HIV capsid inhibitor, with subcutaneous injections <u>every 6 months</u>
- HPTN and Gilead will develop two companion studies in collaboration:
 - HPTN 102/Purpose 3: A lenacapavir Phase 2 PK, safety, acceptability in cis-gender women in the US
 - HPTN 103/Purpose 4: A phase 2 PK, safety, acceptability of lenacapavir in people who inject drugs (PWID) in the US


Broadly Neutralizing Antibodies for HIV Prevention





Broadly Neutralizing Antibodies





Antibody Mediated Prevention Trials





ORIGINAL ARTICLE


Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

L. Corey, P.B. Gilbert, M. Juraska, D.C. Montefiori, L. Morris, S.T. Karuna,
S. Edupuganti, N.M. Mgodi, A.C. deCamp, E. Rudnicki, Y. Huang, P. Gonzales, R. Cabello, C. Orrell, J.R. Lama, F. Laher, E.M. Lazarus, J. Sanchez, I. Frank,
J. Hinojosa, M.E. Sobieszczyk, K.E. Marshall, P.G. Mukwekwerere, J. Makhema, L.R. Baden, J.I. Mullins, C. Williamson, J. Hural, M.J. McElrath, C. Bentley, S. Takuva, M.M. Gomez Lorenzo, D.N. Burns, N. Espy, A.K. Randhawa,
N. Kochar, E. Piwowar-Manning, D.J. Donnell, N. Sista, P. Andrew, J.G. Kublin,
G. Gray, J.E. Ledgerwood, J.R. Mascola, and M.S. Cohen, for the HVTN 704/ HPTN 085 and HVTN 703/HPTN 081 Study Teams*

- VRC01 is a broadly neutralizing antibody (bNAb) which blocks the CD4 binding site on the HIV envelope
- VRC01 was infused every 2 months x 10 to high-risk women (Africa) and MSM and transgender individuals (Americas) (n=4,600)
- Two doses of VRC01 were evaluated: 10 mg/kg and 30 mg/kg

VRCO1 neutralized highly sensitive viruses, no effect on others

HIV bnAb clinical trials in HIV-uninfected adults




HVTN/HPTN HIV bnAb Clinical Trials in HIV-uninfected adul > 4900 participants > 50 sites

Clinical Trial Participants	Start	bnAb	New concepts ¹	Key results – the road to combo-AMP	countries 11 countries		
HVTN 104 N=88	2014	VRC01 IV, SC	Safety, PK, PD, neutralizationRepeat dosing up to 22 weeks				
HVTN 704/HPTN 085 N= 2699	2016	VRC01 IV	HIV prevention efficacy proof of conceptCorrelate of protection	 HIV bnAb can prevent HIV acquisition Correlate of protection – PT₈₀ biomarker to predict 	Brazil, Peru, USA, Switzerland		
HVTN 703/HPTN 081 N=1924	2016	VRC01 IV	HIV prevention efficacy proof of conceptCorrelate of protection	 protection HIV bnAbs are safe – safety profile equal to placebo 	Botswana, Kenya, Malawi, Mozambique, South Africa, Tanzania, Zimbabwe		
HVTN 116 N=80	2017	VRC01 IV VRC01LS IV	 LS modification, longer half-life Mucosa, tissue & secretions PK & activity 	 VRC01LS ~3x longer half-life in serum, higher and prolonged levels in genital and rectal tissue 	South Africa, USA		
HVTN 127/HPTN 087 N=124	2018	VRC07-523LS IV, IM, SC	IM dosing	 VRC07-523LS ~2x longer half life Neutralization consistent after 5 doses 	Switzerland, USA		
HVTN 128 N=28	2019	VRC07-523LS IV	Mucosa PK & activity		USA		
HVTN 130/HPTN 089 N=27	2019	 VRC07-523LS IV 10-1074 IV PGT121 IV PGDM1400 IV 	2 bnAb combinations	 No PK interaction No loss of complementary neutralization Greater neutralization coverage in 3 bnAb arms compared to 2 bnAb arms 	USA		
HVTN 136/HPTN 092 N=32	2020	 VCR07-523LS IV, SC PGT121.414.LS IV, SC 	2 LS bnAb combination	PGT121.414.LS ~3x longer half-life	USA		
HVTN 140/HPTN 101 N=95	2021	 VRC07-523LS IV, SC PGT121.414.LS IV, SC PGDM1400LS IV, SC 	 3 LS bnAb combinationFixed dose compared to weight-based dose	PGDM1400LS ~2.5x longer half-life	Kenya, South Africa, USA, Zimbabwe		
HVTN 143/HPTN 109 N=77	2023	 VRC01.23LS IV PGT121.414.LS IV PGDM1400LS IV 	 3 LS bnAb combination 1st of 3 LS bnAbs to be used in 'combo AMP' in a 3 LS bnAb combination – 1 of 3 		South Africa		
HVTN 141/HPTN 105 N= 92	2024	VRC01.23LS IV ePGT121v1LS IV, SC	 2nd (and 1st) of 3 LS bnAbs combination to be used in 'combo AMP' in a 2 LS bnAb combination – 2 of 3 		South Africa, USA		
HVTN TBD/HPTN TBD N= tbd ± 92	2024	 VRC01.23LS IV ePGT121v1LS IV PGDM1400.93LS IV, SC 	 3rd (and 2nd and 1st) of 3 LS bnAbs combination to be used in 'combo AMP' in a 3 LS bnAb combination – 3 of 3 		TBD, South Africa, USA		
HVTN TBD/HPTN TBD N=tbd ± 200	2024	 VRC01.23LS IV ePGT121v1LS IV PGDM1400.93LS IV 	 Fixed 'combo-AMP' dose compared to weight-based dose Safety run-in for combo-AMP 		TBD, South Africa, USA		
Combo-AMP studies 1. Women in SSA 2. MSM & transgender N=tbd	2025/ 2026	 VRC01.23LS IV ePGT121v1LS IV PGDM1400.93LS IV 	 3 LS bnAbs combination HIV prevention efficacy proof of concept Correlate of protection 		AMP countries, TBD		

¹All trials evaluate safety, PK, & serum neutralization; additional protocol-specific evaluations noted here.

HIV bnAb clinical trials in HIV-uninfected adults





NIH Criteria for a bNab PreP Trial



- Pharmacology leads to a stable combination (i.e.no "tails")
- A product manufacturer
- A commercial partner
- An ethical trial design
- Feasible implementation

Dual Prevention Pill: HPTN 104



Phase 2b, open label, randomized crossover study of DPP (co-formulated F/TDF+ ethynyl estradiol/levonorgestrel oral contraceptive pill (OCP), compared with the two tablets with daily oral F/TDF + OCP (2PR) for PrEP and pregnancy prevention in HIV-uninfected women

Sample Size: ~300 women 16-39 years (100 adolescents) for 48 weeks per participant Regulatory Sponsor: Viatris


Primary Objective:

Compare PrEP adherence to the DPP versus 2PR during a randomized crossover period Pivotal Bioequivalence results to be submitted to US FDA 2023


Speculation: Study launched 2024. Aspiration {US FDA approval 2025!!

Back to STIs and the HIV "Syndemic"





Among cases with reported HIV status, 44% among MSM were HIV+, compared with 38% among men with unknown sex of sex partners, 7.1% among men who have sex with women only, and 3.9% among women



Percent with primary and secondary syphilis was higher for HIV+ compared with those not (12% vs 4.9%), similar to urogenital chlamydia (6.2% vs 5.4%) and gonorrhea (12% vs 7.8%)

A Phase II randomized, observer-blind, placebo-controlled study to assess efficacy of meningococcal Group B vaccine MenB+OMV NZ (Bexsero) in preventing gonococcal infection (DMID Protocol 19-0004/HPTN 108)

Study design	Phase II, randomised, observer-blind, placebo-controlled trial (USA and Thailand)
Primary objective	Bexsero efficacy in preventing urogenital and/or anorectal gonococcal infection

Subjects at risk of <i>N. gonorrhoeae</i> infection	Bexsero	Frink	5	Findt			i		
	Randomised	0	1	2	3	6	9	12	15 months
N=~2200, aged 18–50 years	Placebo	COM	لر	ECON		Ĥ	Ĥ	Ĥ	

Key:

reatment

Clinic

visit

assess safety

Recruiting estimated completion 2024 Target enrolment 2,200 to achieve 202 incident infections Current enrolment 667 across 11 sites

3 HPTN Sites in the US and (soon) Malawi

Clinical trials.gov. NCT04350138. https://clinicaltrials.gov/ct2/show/NCT04350138 (accessed September 2022)

US Vanguard Integrated Strategies



<u>HPTN 091</u>: HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas

<u>HPTN 094</u>: A Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care

<u>HPTN 096</u>: Getting to Zero among Black MSM in the American South: Testing the Efficacy of an Integrated Strategy

Approved Evolving Concepts



- HPTN 111: Uptake of HIV Self-testing and Linkage to Prevention and Care among Heterosexual Men Attending Barbershops in Uganda: A Cluster Randomized Trial
- HPTN 112: Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Sub-Saharan Africa: Examining the Feasibility, Acceptability, and Associated Costs of a Systems-Navigator-Delivered Integrated Prevention Package
- HPTN 113: Double Prevention: A Vanguard Study of an Integrated Strategy of HIV PrEP and STI PEP for Young Latino Sexual Minority Men (SMM) in the Americas

Community Engagement







Community Engagement is pivotal part of all HPTN studies.

A few examples:

- Advocacy for affordable post-trial access to CAB LA in countries where HPTN 083 and HPTN 084 are being conducted
- Participating in the development of all forthcoming HPTN research initiatives
- Contributed "Including pregnant and breastfeeding people in trials of novel LAED PrEP agents – perspectives from sub-Saharan Africa community stakeholders" in JIAS Special Issue



Domestic Program established in 2010

• 48 Scholars to date

International Program established in 2015

• 15 Scholars to date

60+ Scholars since 2010 (some were in multiple cohorts)

- 34% men; 66% women
- 20 datasets: HPTN 037-HPTN 082
- 50+ mentors

HPTN involvement

- Protocol Team Members (HPTN 073, 078, 094, 096)
- Protocol Team Leadership (HPTN 091, HPTN 096)
- Memberships/Observerships: Black Caucus, Scientific Committees, and Working Groups



2022-2023 HPTN Scholars





Dr. Tina Herrera



Dr. David Zelaya



Dr. Donte Boyd



Dr. Waru Gichane



Dr. Sophia Zamudio-Haas Dr. Victoria Ndyanabangi



Kudzai Hlahla

Acknowledgments



Thank you very much to all study participants, investigators and site staff, community groups, collaborators and funders

Overall support for the HIV Prevention Trials Network (HPTN) is provided by:

- National Institute of Allergy and Infectious Diseases (NIAID)
- Office of the Director (OD), National Institutes of Health (NIH)
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- ViiV Healthcare, Gilead Sciences, The Bill and Melinda Gates Foundation, and Viatris
- Collaborations with HVTN, ACTG, IAVI, AVAC and Rockefeller University

Award Numbers UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center).

f D y @ ∣ @HIVptn

31